• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Global Botulinum Toxin Industry


News provided by

Reportlinker

May 16, 2012, 10:55 ET

Share this article

Share this article


NEW YORK, May 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Botulinum Toxin Industry

http://www.reportlinker.com/p0119494/Global-Botulinum-Toxin-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_D

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Product Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.The report profiles 22 companies including many key and niche players such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, Revance Therapeutics, Inc., and US WorldMeds. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Cosmetic Applications I-3

Therapeutic Applications I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Prelude II-1

Current and Future Scenario II-1

By Geographic Region II-1

Botulinum Toxin: "The Science, The Hopes & the Risks" II-2

Developed Regions Continue to Hold Sway Over Global Botulinum

Toxin Market II-2

Developing Markets Not Far Behind, But Not Yet There II-3

Pharma Companies Keenly Eye Lucrative BT Market II-3

2. TRENDS & ISSUES II-5

Acceptance for Cosmetic BTX Treatment Grows II-5

Aging Population: A Weighty Demographic Driver II-5

Unmet Medical Needs Encourage Off-Label Use: A Cause for

Concern or Jubilation? II-5

Urgent Need for Physician Education about Off Label Usage II-6

High Voltage Ad Campaigns Boost Patient Awareness II-6

Societal Pressure to Look Young, Drives up Demand for Facial

Aesthetics II-6

Financing of Non-Reimbursed Healthcare: The Need of the Hour II-7

Combination Therapies: A Double Whammy Success II-7

Short Lived Aesthetic Effects: A Strong Business Case for

Revision Treatments II-8

Consolidation Blows in the Aesthetic Healthcare Industry II-8

Undesirable Side Effects: A Challenge to Reckon With II-8

Immunogenicity Undermines Patient Compliance II-9

Protein Free BTX Products - The Probable Answer for

Immunogenicity II-9

Antigenicity: One of the Most Problematic Issues in Drug

Development II-10

Stringent Regulations Delay Market Approval & Put

Reimbursements in Limbo II-10

Non-Injectable Alternatives to Turn On the Heat II-10

Alternative Methods of Botulinum Application under

Development - A Review II-11

Fears of Terrorism & Biological Warfare Thwart International

Trade II-11

3. PRODUCT/INDUSTRY DYNAMICS II-12

Comparison of Botox®, Dysport® and Xeomin® by Indications and

Year of Approval II-12

Scarce Differentiation Between the Four Approved BTX Products II-13

Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin

by Safety and Efficacy II-13

Botox® - An Overview II-14

Key Characteristics of Botox® and Botox® Cosmetic II-14

Common Adverse Reactions with Botox II-15

Approvals and Indications of Botox in Select Regions II-15

Global Botox Sales Shoot Up, Competition Begins to Hurt

Prospects II-15

Migraine Indication to Bolster Allergan's Botox Sales II-16

Allergan Commences Advertising for Botox in Migraine

Settings in the US II-16

Therapeutics to Offer Higher Prospects for Botox II-17

Botox Therapeutic Approvals in the US by Indication II-17

Dysport® II-17

Key Characteristics of Dysport® II-18

Ipsen Counts on New Indications for Future Growth of Dysport II-18

Dysport Therapeutic Development Pipeline by Region II-18

Dysport Cosmetic Development Pipeline by Region II-19

Next Generation Dysport - A Breakthrough in BTX Market on the

Cards II-19

Xeomin® II-19

Key Characteristics of Xeomin® II-19

Xeomin Development Pipeline: Approved and Investigational

Indications as of 2011 II-20

Global Expansion Helps Merz Gain in the BTX Market II-20

Myobloc®/NeuroBloc® II-20

Key Characteristics of Myobloc® II-21

Myobloc - Still Long Way to Go II-21

Meditoxin® II-21

Meditoxin® Expanding Its Wings across the Globe II-21

PurTox® II-22

Key Characteristics of PurTox® II-22

PurTox Beckons Success in Clinical Trial Stage, Launch Still

Years Away II-22

RT001 II-22

Revance's RT001 -Potential Revolution in BTX Market under

Development II-22

How Does RT001 Work? II-23

RT001 - A Potential Convenient Treatment Option for

Hyperhydrosis Patients II-23

4. COMPETITION II-24

Allergan Wields the Scepter II-24

Allergan's Botox Faces the Heat of Competition II-24

Market Share Statistics II-24

Global II-24

Table 1: Leading Products in the Global Botulinum Toxin

Market (2011E): Percentage Breakdown of Revenue for Botox,

Dysport, Xeomin and Others (includes corresponding

Graph/Chart) II-24

Table 2: World Market for Therapeutic Neurotoxins (2011E):

Percentage Breakdown of Revenues by Brand -Botox, Dysport,

Xeomin and Others (includes corresponding Graph/Chart) II-25

Table 3: World Market for Cosmetic Neurotoxins (2011E):

Percentage Breakdown of Revenues by Brand - Botox, Dysport,

Xeomin and Others (includes corresponding Graph/Chart) II-25

5. PRODUCT OVERVIEW II-26

Botulinum Toxin: A Poison That Cures II-26

Structure & Mechanism of Action II-26

Disadvantages II-27

Classification of Botulinum Toxin II-27

Botulinum Toxin Type A II-27

Historical Timeline of Botulinum Toxin: 1885-2002 II-28

Botulinum Toxin Type B II-28

Applications of Botulinum Toxin II-29

Cosmetic Applications II-29

Glabellar Lines II-29

Facial Wrinkles II-29

Key Cosmetic Indications for Botulinum Toxin II-29

Therapeutic Applications II-30

Movement Disorders/Pain II-30

Cervical Dystonia II-30

Hemifacial Spasm II-30

Blepharospasm II-31

Strabismus II-31

Chronic Pain II-31

Botox in Migraine Treatment II-31

Hyperhidrosis II-32

Bladder Dysfunctions II-32

Spasticity II-32

Other Applications II-33

Side Effects II-34

An Overview of Side Effects of BTX Treatment II-34

Table 4: Side-Effects of BOTOX Treatment for Urinary

Incontinence Associated with Neuromuscular Disorders:

Percentage Breakdown of Major Conditions Reported Within 12

weeks of Injections during Phase III Clinical Trials

(includes corresponding Graph/Chart) II-34

Table 5: Side-Effects of BOTOX Treatment for Urinary

Incontinence Associated with Neuromuscular Disorders:

Percentage Breakdown of Major Conditions Reported Within 44

weeks of Injections during Phase III Clinical Trials

(includes corresponding Graph/Chart) II-35

6. PRODUCT INTRODUCTIONS/APPROVALS II-36

Botox Receives Health Canada Approval for Treating Neurogenic

Bladder Condition II-36

Allergan Obtains FDA Approval for New In -Vitro Cell-Based

Assay for BOTOX II-36

Merz Aesthetics Obtains FDA Approval for XEOMIN® for Treating

Glabellar Lines II-36

IMB Recommends Botox for Urinary Incontinence Management in

Neurognenic OAB in EU II-37

FDA Approves Botox for Treating Urinary Incontinence in

Neurogenic OAB Patients II-37

Allergan Receives Health Canada Approval for Botox for

Treating Chronic Migraine II-38

BOTOX® Receives Approval for Treating Chronic Headaches II-38

Eisai's NerBloc Intramuscular Injection Approved for Sale in

Japan. II-38

SMC Approves the Use of Botox® for the Treatment of Focal

Spasticity II-38

FDA Grants Approval for Botox for Treating Migraine II-39

MHRA Grants Approval for Botox for Treating Chronic Migraine II-39

Allergan Receives FDA Approval for Botox for Treating Upper

Limb Spasticity II-39

Russian Authorities Approve Xeomin for Cosmetic Applications II-39

Merz Launches Xeomin in the US II-39

Ipsen Launches Dysport in US II-40

Ipsen and Medicis Receives FDA Approval for Dysport™ II-40

Xeomin Receives Approval From European Health Authorities II-41

Ranbaxy and MedyTox Collaborates to Launch Neuronox II-41

GlaxoSmithKline Receives Approval for Botox Vista II-41

Galderma and Ipsen Obtain Marketing Authorization for Azzalure II-41

Azzalure® Gains Approval from 15 European Countries II-41

Inclusion of New Side Effect in Botox and Botox Cosmetic Labels II-42

Azzalure® Gains Approval for Aesthetic Application in the UK II-42

Allergan and Clinique Launch New Skin Care Products II-43

FDA Accepts Ipsen's Filing for Reloxin II-43

GlaxoSmithKline Gains Approval for BOTOX® in Japan II-43

Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type

A Product II-43

Allergan Commences Botox Study for Urological Cases in India II-43

FDA Accepts BLA Filing for Dysport® in Cervical Dystonia Cases II-44

Allergan Successfully Completes Analysis of Two Phase III

Trials for BOTOX® II-44

Allergan to Launch New Products in India II-44

7. RECENT INDUSTRY ACTIVITY II-45

Amgen Inc Acquires Brazilian Company Bergamo II-45

Ipsen and Syntaxin Forge Agreement to Formulate Novel

Botulinum Toxin Product II-45

Xoma Bags Federal Contract to Develop Broad-Spectrum Antitoxins II-45

US WorldMeds Takes Over Solstice Neurosciences II-45

Merz Pharma Acquires BioForm Medical II-46

Johnson & Johnson Acquires Mentor Corporation II-46

Merz Pharmaceuticals and Biolab Set Up Joint Venture II-47

Ranbaxy Signs an in-Licensing Agreement with Medy-Tox II-47

Ranbaxy Signs Marketing Agreement with MedyTox II-47

Revance and Medicis Sign Licensing Agreement II-47

GlaxoSmithKline and Wakamoto Pharmaceutical Collaborate to

Market Botox II-48

BioForm Medical Acquires Advanced Cosmetic Intervention II-48

Galderma to Acquire CollaGenex II-48

Allergan and Clinique Form Strategic Collaboration II-48

Allergan to Set Up a New Subsidiary in India II-49

Allergan Join Hands with India-Based Kaya II-49

Q-Med and Medy-Tox Cancel the Collaboration Agreement II-49

Galderma to Increase Awareness in Brazil II-49

Galderma Receives License to Market Dysport II-49

8. FOCUS ON SELECT GLOBAL PLAYERS II-50

Allergan, Inc. (US) II-50

Ipsen Group (France) II-50

Lanzhou Institute of Biological Products (China) II-51

Metabiologics, Inc. (US) II-51

Merz Pharma GmbH & Co. KGaA (Germany) II-51

Mentor Corporation (US) II-52

Medy-Tox Incorporated (South Korea) II-52

Medicis Pharmaceutical Corporation (US) II-52

Revance Therapeutics, Inc. (US) II-53

US WorldMeds (US) II-53

9. GLOBAL MARKET PERSPECTIVE II-55

Table 6: World Recent Past, Current & Future Analysis for

Botulinum Toxin by Geographic Region/Country - US, Europe and

Rest of World Markets Independently Analyzed by Annual Sales

in US$ Million for the Years 2010 through 2018 (includes

corresponding Graph/Chart) II-55

Table 7: World Historic Review for Botulinum Toxin by

Geographic Region/Country - US, Europe and Rest of World

Markets Independently Analyzed by Annual Sales in US$ Million

For the Years 2004 through 2009 (includes corresponding

Graph/Chart) II-56

Table 8: World 15-Year Perspective for Botulinum Toxin by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Europe and Rest of World Markets for the Years 2004, 2011

& 2018 (includes corresponding Graph/Chart) II-57

Table 9: World Recent Past, Current & Future Analysis for

Botulinum Toxin in Cosmetic Applications by Geographic Region-

US, Europe and Rest of World Markets Independently Analyzed

by Annual Sales in US$ Million for the Years 2010 through 2018

(includes corresponding Graph/Chart) II-58

Table 10: World Historic Review for Botulinum Toxin in

Cosmetic Applications by Geographic Region - US, Europe and

Rest of World Markets Independently Analyzed by Annual Sales

in US$ Million for the Years 2004 through 2009 (includes

corresponding Graph/Chart) II-59

Table 11: World 15-Year Perspective for Botulinum Toxin in

Cosmetic Applications by Geographic Region - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) II-60

Table 12: World Recent Past, Current & Future Analysis for

Botulinum Toxin in Therapeutic Applications by Geographic

Region - US, Europe and Rest of World Markets Independently

Analyzed by Annual Sales in US$ Million for the Years 2010

through 2018 (includes corresponding Graph/Chart) II-61

Table 13: World Historic Review for Botulinum Toxin in

Therapeutic Applications by Geographic Region - US, Europe and

Rest of World Markets Independently Analyzed by Annual Sales

in US$ Million for the Years 2004 through 2009 (includes

corresponding Graph/Chart) II-62

Table 14: World 15-Year Perspective for Botulinum Toxin in

Therapeutic Applications by Geographic Region - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) II-63

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current and Future Scenario III-1

Cosmetic Procedures: An Overview III-1

Major Market Trends III-2

Botulinum Toxin to Drive Growth in the Facial Aesthetics

Market III-2

Competition Heats Up in the US BTX Market III-2

Booming Non-Surgical Treatments III-2

Aging Baby Boomers Drive Aesthetic Business III-3

Expanding Physician Base Extends Impetus to Growth III-3

Demand for Professional Help On the Rise III-3

Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin III-3

Botulism Poisoning: A Major Concern III-4

Botox Injection - Popular Non-Invasive Cosmetic Procedure III-4

Recession Dents Cosmetic BTX Procedural Volume, Albeit

Slightly III-4

Table 15: US Cosmetic BTX Procedure Volume: 2007-2011

(includes corresponding Graph/Chart) III-4

Botox Therapeutic to Drive Growth in Botox Franchise III-5

Dysport Takes on Botox in the Therapeutic Space III-5

Pricing and Promotions to Help Dysport Gain Market Share in

Cosmetic Arena III-5

Tremendous Prospects in Therapeutics Space for Dysport in

the Long Run III-6

Therapeutic BTX Market - New Entrants Slow in Gaining

Market Share III-6

Botox's Therapeutic Indications (Approved and

Investigational) in the US by Year of Approval/Stage III-6

Cosmetic BTX Market - Competition Threatens Botox Long-Term

Dominance III-7

Key BTX Products and Associated Fillers and Implants in

the Cosmetic Botulinum Toxin Market III-7

Market Opportunities for Botox in Migraine Beckons a Slow Star III-7

Neurogenic OAB - A Relatively Smaller Market Opportunity III-7

Idiopathic OAB Bodes Superior Prospects for Botox III-8

Issues Persist in the Idiopathic OAB Space Dampening Prospects III-8

Xeomin - Will the "Pure" Factor Finds Many Takers? III-9

Xeomin Takes Big Leap in the US III-9

Xeomin's Potential in the US Cosmetic Market III-9

Merz Fortifies Position in the US Facial Injectables Market

with BioForm Acquisition III-10

PurTox Touted to Emerge as a Direct Competitor to Botox in

the US III-10

Competitive Landscape III-11

Botox Leads the US Botulinum Toxin Market III-11

Market Share Statistics III-11

Table 16: US Market for Therapeutic Neurotoxins (2011E):

Percentage Breakdown of Revenues by Brand - Botox, Myobloc,

Dysport and Xeomin (includes corresponding Graph/Chart) III-11

Table 17: US Market for Aesthetic Neurotoxins (2011E):

Percentage Breakdown of Revenues by Brand - Botox and

Dysport (includes corresponding Graph/Chart) III-11

Product Approvals/Launches III-12

Strategic Corporate Developments III-15

Key Players III-18

B.Market Analytics III-21

Table 18: US Recent Past, Current & Future Analysis for

Botulinum Toxin by Application - Cosmetic Applications and

Therapeutic Applications Markets Independently Analyzed by

Annual Sales Figures in US$ Million for the Years 2010

through 2018 (includes corresponding Graph/Chart) III-21

Table 19: US Historic Review for Botulinum Toxin by

Application - Cosmetic Applications and Therapeutic

Applications Markets Independently Analyzed by Annual Sales

Figures in US$ Million for the Years 2004 through 2009

(includes corresponding Graph/Chart) III-22

Table 20: US 15-Year Perspective for Botulinum Toxin by

Application - Percentage Breakdown of Dollar Sales for

Cosmetic Applications and Therapeutic Applications Markets

for the Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-23

2. EUROPE III-24

A.Market Analysis III-24

Current and Future Scenario III-24

European BTX Cosmetics Treatments Market - A Primer III-24

Botox Approvals and Indications in Select European Countries III-24

Botox to Support Radiation Treatments III-24

Botox Loses Market to New Entrants in Europe III-25

Galderma's Azzalure Makes Market Entry in Europe, Gains

Share from Botox III-25

Russia Mandates Registration of BTX Drugs III-25

Market Share Statistics III-25

Table 21: European Market for Therapeutic Neurotoxins

(2011E): Percentage Breakdown of Revenues by Brand -Botox,

Dysport, Xeomin, and Neurobloc (includes corresponding

Graph/Chart) III-25

Table 22: European Market for Cosmetic Neurotoxins (2011E):

Percentage Breakdown of Revenues by Brand - Botox

(Vistabel/Vistabex), Dysport and Xeomin (includes

corresponding Graph/Chart) III-26

Product Approvals and Launches III-26

Strategic Corporate Development III-28

Key Players III-29

B.Market Analytics III-30

Table 23: European Recent Past, Current & Future Analysis

for Botulinum Toxin by Application - Cosmetic Applications

and Therapeutic Applications Markets Independently Analyzed

by Annual Sales Figures in US$ Million for the Years 2010

through 2018 (includes corresponding Graph/Chart) III-30

Table 24: European Historic Review for Botulinum Toxin by

Application -Cosmetic and Therapeutic Markets Independently

Analyzed by Annual Sales Figures in US$ Million for the

Years 2004 through 2009 (includes corresponding Graph/Chart) III-31

Table 25: European 15-Year Perspective for Botulinum Toxin

by Application - Percentage Breakdown of Dollar Sales for

Cosmetic Applications and Therapeutic Applications Markets

for the Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-32

3. REST OF WORLD III-33

A.Market Analysis III-33

Current and Future Scenario III-33

A Peek into Select Markets III-33

India - An Emerging Market for Botox III-33

South Korean BTX Market - An Overview III-33

Table 26: Botulinum Toxin Demand in South Korea: 2007-

2011E List of Botulinum Toxin Products Sold in South Korea

by Year of Launch (includes corresponding Graph/Chart) III-34

List of Botulinum Toxin Products Sold in South Korea by

Year of Launch III-34

Meditoxin Dominates Domestic BTX Market III-34

Table 27: Korean Botulinum Toxin Market (2010): Percentage

Breakdown of Sales by Leading Players -Medy-Tox, Allergan,

Ipsen, and Lanzhou Institute (includes corresponding

Graph/Chart) III-34

Australia - A Well Supported Market III-35

Botox Approvals and Indications in Select Asian Countries III-35

Latin America- Cosmetic Surgery Market III-35

Botox Approvals and Indications in Select Latin American

Regions III-36

Botox Approvals and Indications in Other Select Global

Regions III-36

Product Approvals and Launches III-37

Strategic Corporate Developments III-38

Key Players III-41

B.Market Analytics III-42

Table 28: Rest of World Recent Past, Current & Future

Analysis for Botulinum Toxin by Application - Cosmetic and

Therapeutic Markets Independently Analyzed by Annual Sales

Figures in US$ Million for the Years 2010 through 2018

(includes corresponding Graph/Chart) III-42

Table 29: Rest of World Historic Review for Botulinum Toxin

by Application - Cosmetic and Therapeutic Markets

Independently Analyzed by Annual Sales Figures in US$

Million for the Years 2004 through 2009 (includes

corresponding Graph/Chart) III-43

Table 30: Rest of World 15-Year Perspective for Botulinum

Toxin by Application - Percentage Breakdown of Dollar Sales

for Cosmetic Applications and Therapeutic Applications

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-44

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 22 (including Divisions/Subsidiaries - 26)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 9

Japan 3

Europe 7

France 1

Germany 2

The United Kingdom 3

Rest of Europe 1

Asia-Pacific (Excluding Japan) 7

------------------------------------------

To order this report:

Medical Devices Industry: Global Botulinum Toxin Industry

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Modal title

Also from this source

Global Public Relations (PR) Tools Market to Reach $20.9 Billion by 2027

Global Public Relations (PR) Tools Market to Reach $20.9 Billion by 2027


The Global Climbing Gym Market is forecast to grow by $4185.74 mn during 2022-2027, accelerating at a CAGR of 12.5% during the forecast period

The Global Climbing Gym Market is forecast to grow by $4185.74 mn during 2022-2027, accelerating at a CAGR of 12.5% during the forecast period

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Surveys, Polls and Research

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.